Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Plasma-Circulating Mir-638, Mir-6511B-5P, Mir-3613-5P, Mir-455-3P, Mir-5787, and Mir-548A-3P As Noninvasive Biomarkers of Immune Reconstitution Post-Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Publisher



Izadifard M1 ; Ahmadvand M2 ; Chahardouli B1 ; Vaezi M1 ; Janbabai G1 ; Seghatoleslami G3 ; Bahrami M3 ; Yaghmaie M1 ; Barkhordar M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Mashhad University of Medical Sciences, Mashhad, Iran

Source: Transplant Immunology Published:2025


Abstract

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a viable treatment option for acute myeloid leukemia (AML), though it carries risks including delayed immune reconstitution and hematopoietic reconstitution failure. This study aimed to explore the potential of circulating miRNA levels as biomarkers for post-transplant immune reconstitution. Methods: This observational study was carried out on de novo non-M3 AML patients receiving allo-HSCT from HLA-matched sibling donors at Shariati Hospital, Iran in 2020–2023. Accordingly, the immunophenotype of NK cells, T cells, and B cells was determined by ten-color multiparameter flow cytometry on blood samples collected pre-transplantation and at day +30 post-transplantation. Concurrently, plasma levels of miR-638, miR-6511b-5p, miR-3613-5p, miR-455-3p, miR-5787, and miR-548a-3p were quantified using quantitative reverse transcription–polymerase chain reaction (RT qPCR). Results: The expression of miR-638, miR-3613-5p, miR-455-3p, and miR-548a-3p positively correlated with CD4+ T cells, CD4+/CD8+ T cell ratio, CD3−/16+/56− cells, and platelet count. Elevated miR-455-3p and miR-3613-5p expressions were associated with higher CD3−/16+/56− cells (P = 0.0475 and P = 0.0325, respectively). Similarly, miR-638 upregulation correlated with increases in CD4+ T cells (P = 0.0112) and the CD4+/CD8+ T cell ratio (P = 0.006), while miR-548a-3p upregulation was associated with increases in the CD4+/CD8+ T cell ratio (P = 0.0353) and platelet count (P = 0.0191). Conversely, miR-3613-5p and miR-6511b-5p had considerable negative correlations with CD8+ T cells (P = 0.03 and P = 0.0246, respectively), whereas miR-5787 negatively correlated with CD3+/16−/56+ cells (P = 0.025). Conclusion: Our findings suggest that differentiation of cell subpopulations is regulated by specific miRNAs. Furthermore, miRNA-based strategies may be developed for immunotherapeutic treatments of AML. © 2025
Other Related Docs
9. Microrna Frontiers: Illuminating Early Detection Paths in Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2025)